A Comparative Clinical Evaluation of Ultrasound-guided Acupotomy Combined with Extracorporeal Shock Wave Therapy for Nonspecific Low Back Pain.

J Vis ExpSep 15, 2026 (epub)
Clinical ResearchPhysical Medicine & Rehabilitation

Fengjiao Zhang, Lei Liu, Liangliang Wang et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the efficacy of ultrasound-guided acupotomy combined with extracorporeal shock wave therapy (ESWT) for nonspecific low back pain (NLBP) in 90 patients. The combined treatment group showed significantly lower visual analog scale (VAS) and Oswestry Disability Index (ODI) scores, higher Japanese Orthopaedic Association (JOA) scores, and an overall effective rate of 93.33% compared to monotherapy groups.

Key findings

  • The combined treatment group had a 93.33% overall effective rate.
  • VAS scores were significantly lower in the combined group compared to monotherapy.
  • ODI scores were significantly lower in the combined group compared to monotherapy.
  • JOA scores were significantly higher in the combined group compared to monotherapy.

Why it matters

The findings suggest that combining ultrasound-guided acupotomy with ESWT may enhance treatment outcomes for patients with nonspecific low back pain, potentially offering a more effective therapeutic option.

Source

PubMed · PMID 42747017

Published in J Vis Exp. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.